Works matching AU Xuezhi Hao

Results: 86

A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.

Published in:

Oncologist, 2020, v. 25, n. 5, p. e833, doi. 10.1634/theoncologist.2019-0391

By:

Liu, Yutao;
Hu, Xingsheng;
Jiang, Jun;
Yang, Lin;
Zhou, Shengyu;
Liu, Peng;
Li, Junling;
Wang, Yan;
Hao, Xuezhi;
Shi, Yuankai

Publication type:

Article

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study.

Published in:

Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221082339

By:

Yang, Guangjian;
Yang, Yaning;
Liu, Runze;
Li, Weihua;
Xu, Haiyan;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan;
Zhang, Shuyang;
Ai, Xin;
Xu, Fei;
Wang, Yan

Publication type:

Article

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).

Published in:

BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02738-5

By:

Shi, Yuankai;
Chen, Jianhua;
Zhang, Helong;
Zhang, Zhihong;
Zhang, Yiping;
Wang, Zhehai;
Zhang, Shucai;
Zhao, Jian;
Liu, Chunling;
Wang, Xiuwen;
Zhao, Yanqiu;
Hu, Changlu;
Yang, Lei;
Hao, Xuezhi;
Wang, Lin;
Liu, Yunpeng;
Yu, Yan;
Zhao, Jun;
Wang, Mengzhao;
Zhang, Liangming

Publication type:

Article

Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review.

Published in:

BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-13155-z

By:

Lei, Siyu;
Tian, Linyan;
Yang, Lu;
Yang, Yaning;
Li, Junling;
Hu, Xingsheng;
Hao, Xuezhi;
Xu, Haiyan;
Wang, Yan

Publication type:

Article

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.

Published in:

Community Practitioner, 2021, v. 94, n. 6, p. 1040, doi. 10.20892/j.issn.2095-3941.2020.0450

By:

Huihui Yin;
Lu Yang;
Gongxin Peng;
Ke Yang;
Yuling Mi;
Xingsheng Hu;
Xuezhi Hao;
Yuchen Jiao;
Xiaobing Wang;
Yan Wang

Publication type:

Article

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study.

Published in:

Cancer Medicine, 2019, v. 8, n. 13, p. 5823, doi. 10.1002/cam4.2420

By:

Yang, Guangjian;
Ma, Di;
Xu, Haiyan;
Yang, Lu;
Li, Junling;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Yan

Publication type:

Article

A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.

Published in:

Cancer Medicine, 2016, v. 5, n. 6, p. 1116, doi. 10.1002/cam4.689

By:

Mo, Hongnan;
Hao, Xuezhi;
Liu, Yutao;
Wang, Lin;
Hu, Xingsheng;
Xu, Jianping;
Yang, Sheng;
Xing, Puyuan;
Shi, Youwu;
Jia, Bo;
Wang, Yan;
Li, Junling;
Wang, Hongyu;
Wang, Ziping;
Sun, Yan;
Shi, Yuankai

Publication type:

Article

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes.

Published in:

Frontiers in Oncology, 2021, v. 12, p. 1, doi. 10.3389/fonc.2021.713483

By:

Xu, Haiyan;
Yang, Guangjian;
Li, Weihua;
Li, Junling;
Hao, Xuezhi;
Xing, Puyuan;
Yang, Yaning;
Wang, Yan

Publication type:

Article

Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.

Published in:

Journal of Translational Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12967-024-05388-0

By:

Wu, Lige;
Zou, Zihua;
Li, Yan;
Hao, Xuezhi;
Ying, Jianming;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.

Published in:

BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10676-x

By:

Xu, Ziyi;
Hao, Xuezhi;
Wang, Qi;
Yang, Ke;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.

Published in:

2019

By:

Mu, Yuxin;
Hao, Xuezhi;
Yang, Ke;
Ma, Di;
Wang, Shouzheng;
Xu, Ziyi;
Li, Junling;
Xing, Puyuan

Publication type:

journal article

Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.

Published in:

2019

By:

Xing, Puyuan;
Wang, Shouzheng;
Wang, Qiang;
Ma, Di;
Hao, Xuezhi;
Wang, Mengzhao;
Wang, Yan;
Shan, Li;
Xin, Tao;
Liang, Li;
Liang, Hongge;
Du, Yang;
Zhang, Zhaohui;
Li, Junling

Publication type:

journal article

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer.

Published in:

Journal of Cellular & Molecular Medicine, 2019, v. 23, n. 10, p. 6812, doi. 10.1111/jcmm.14565

By:

Xing, Puyuan;
Han, Xiaohong;
Wang, Sha;
Liu, Yutao;
Yang, Sheng;
Hao, Xuezhi;
Wang, Yan;
Liu, Peng;
Li, Junling;
Wang, Lin;
Chang, Lianpeng;
Guan, Yanfang;
Zhang, Zhishang;
Wu, Di;
Yao, Jiarui;
Yi, Xin;
Shi, Yuankai

Publication type:

Article

Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma.

Published in:

Cancer (0008543X), 2023, v. 129, n. 24, p. 3873, doi. 10.1002/cncr.34967

By:

Wang, Shouzheng;
Xie, Tongji;
Li, Yan;
Guo, Lei;
Ying, Jianming;
Wang, Yan;
Hao, Xuezhi;
Wang, Xingyuan;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).

Published in:

BMC Medicine, 2022, v. 20, n. 1, p. 1, doi. 10.1186/s12916-022-02470-6

By:

Yang, Guangjian;
Xu, Haiyan;
Yang, Yaning;
Zhang, Shuyang;
Xu, Fei;
Hao, Xuezhi;
Li, Junling;
Xing, Puyuan;
Hu, Xingsheng;
Liu, Yutao;
Wang, Lin;
Lin, Lin;
Wang, Zhijie;
Duan, Jianchun;
Wang, Jie;
Wang, Yan

Publication type:

Article

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.

Published in:

2022

By:

Zou, Zihua;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Yan;
Song, Xia;
Shan, Li;
Zhang, Cuiying;
Liu, Ziling;
Ma, Kewei;
Dong, Guilan;
Li, Junling

Publication type:

journal article

Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas.

Published in:

Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-01981-3

By:

Li, Yan;
Xie, Tongji;
Wang, Shouzheng;
Yang, Lin;
Hao, Xuezhi;
Wang, Yan;
Hu, Xingsheng;
Wang, Lin;
Li, Junling;
Ying, Jianming;
Xing, Puyuan

Publication type:

Article

Clinicopathologic characteristics and outcome of patients with different EGFR mutations.

Published in:

Asia Pacific Journal of Clinical Oncology, 2019, v. 15, n. 3, p. 166, doi. 10.1111/ajco.13072

By:

Zhou, Shengyu;
Hu, Xingsheng;
Wang, Yan;
Li, Junling;
Zhou, Liqiang;
Hao, Xuezhi;
Liu, Yutao;
Shi, Yuankai

Publication type:

Article

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.

Published in:

Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 11, p. 3081, doi. 10.1007/s00432-021-03901-2

By:

Xu, Ziyi;
Hao, Xuezhi;
Yang, Ke;
Wang, Qi;
Wang, Jing;
Lin, Lin;
Teng, Fei;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.

Published in:

Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 9, p. 2427, doi. 10.1007/s00432-020-03239-1

By:

Mu, Yuxin;
Hao, Xuezhi;
Xing, Puyuan;
Hu, Xingsheng;
Wang, Yan;
Li, Teng;
Zhang, Jinyao;
Xu, Ziyi;
Li, Junling

Publication type:

Article

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2 -Targeted Tyrosine Kinase Inhibitors.

Published in:

Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.806737

By:

Yang, Guangjian;
Xu, Haiyan;
Hu, Jiaqi;
Liu, Runze;
Hu, Peizeng;
Yang, Yaning;
Li, Weihua;
Hao, Xuezhi;
Zhang, Shuyang;
Xu, Fei;
Ai, Xin;
Li, Junling;
Wang, Yan

Publication type:

Article

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer.

Published in:

Frontiers in Pharmacology, 2021, v. 12, p. 1, doi. 10.3389/fphar.2021.573852

By:

Hao, Xuezhi;
Shen, Aizong;
Wu, Bin

Publication type:

Article

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer.

Published in:

Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00603

By:

Mu, Yuxin;
Yang, Ke;
Hao, Xuezhi;
Wang, Yan;
Wang, Lin;
Liu, Yutao;
Lin, Lin;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma.

Published in:

Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00556

By:

Han, Xiaohong;
Tan, Qiaoyun;
Yang, Sheng;
Li, Junling;
Xu, Jianping;
Hao, Xuezhi;
Hu, Xingsheng;
Xing, Puyuan;
Liu, Yutao;
Lin, Lin;
Gui, Lin;
Qin, Yan;
Yang, Jianliang;
Liu, Peng;
Wang, Xingyuan;
Dai, Wumin;
Lin, Dongmei;
Lin, Hua;
Shi, Yuankai

Publication type:

Article

Frequency control strategy of multi‐area hybrid power system based on frequency division and sliding mode algorithm.

Published in:

IET Generation, Transmission & Distribution (Wiley-Blackwell), 2019, v. 13, n. 8, p. 1145, doi. 10.1049/iet-gtd.2018.5145

By:

Mi, Yang;
He, Xingtang;
Hao, Xuezhi;
Li, Zhenkun;
Fu, Yang;
Wang, Chengshan;
Wang, Jianhui

Publication type:

Article

Sliding mode load frequency control for multiarea time-delay power system with wind power integration.

Published in:

IET Generation, Transmission & Distribution (Wiley-Blackwell), 2017, v. 11, n. 18, p. 4644, doi. 10.1049/iet-gtd.2017.0600

By:

Yang Mi;
Xuezhi Hao;
Yongjuan Liu;
Yang Fu;
Chengshan Wang;
Peng Wang;
Poh Chiang Loh

Publication type:

Article

Sliding mode load frequency control for multi‐area time‐delay power system with wind power integration.

Published in:

IET Generation, Transmission & Distribution (Wiley-Blackwell), 2017, v. 11, n. 18, p. 4644, doi. 10.1049/iet-gtd.2017.0600

By:

Mi, Yang;
Hao, Xuezhi;
Liu, Yongjuan;
Fu, Yang;
Wang, Chengshan;
Wang, Peng;
Loh, Poh Chiang

Publication type:

Article

Prognostic significance of CD276 in non-small cell lung cancer.

Published in:

Open Medicine, 2019, v. 14, n. 1, p. 805, doi. 10.1515/med-2019-0076

By:

Changgong Zhang;
Xuezhi Hao

Publication type:

Article

Expression of CENPE and its prognostic role in non-small cell lung cancer.

Published in:

Open Medicine, 2019, v. 14, n. 1, p. 497, doi. 10.1515/med-2019-0053

By:

Xuezhi Hao;
Tao Qu

Publication type:

Article

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China.

Published in:

Cancer Medicine, 2023, v. 12, n. 1, p. 335, doi. 10.1002/cam4.4852

By:

Yang, Guangjian;
Yang, Yaning;
Liu, Runze;
Li, Weihua;
Xu, Haiyan;
Hao, Xuezhi;
Li, Junling;
Zhang, Shuyang;
Xu, Fei;
Lei, Siyu;
Wang, Yan

Publication type:

Article

The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.

Published in:

Cancer Biology & Medicine, 2021, v. 18, n. 4, p. 1040, doi. 10.20892/j.issn.2095-3941.2020.0450

By:

Huihui Yin;
Lu Yang;
Gongxin Peng;
Ke Yang;
Yuling Mi;
Xingsheng Hu;
Xuezhi Hao;
Yuchen Jiao;
Xiaobing Wang;
Yan Wang

Publication type:

Article

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.920709

By:

Puyuan Xing;
Xuezhi Hao;
Xin Zhang;
Junling Li

Publication type:

Article

First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes.

Published in:

Thoracic Cancer, 2025, v. 16, n. 11, p. 1, doi. 10.1111/1759-7714.70095

By:

You, Mengxing;
Wu, Lige;
Liu, Jiayu;
Yuan, Hanqi;
Wang, Zihe;
Hao, Xuezhi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

A Real‐World Study: Therapeutic Outcomes of ROS1‐Positive Advanced NSCLC.

Published in:

Thoracic Cancer, 2025, v. 16, n. 9, p. 1, doi. 10.1111/1759-7714.70086

By:

Yuan, Hanqi;
Zou, Zihua;
Hao, Xuezhi;
Li, Yan;
Li, Junling;
Ying, Jianming;
Xing, Puyuan

Publication type:

Article

Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer.

Published in:

Thoracic Cancer, 2025, v. 16, n. 2, p. 1, doi. 10.1111/1759-7714.70000

By:

Zou, Zihua;
Wu, Lige;
Hao, Xuezhi;
Li, Yan;
Liang, Li;
Gu, Yangchun;
Ying, Jianming;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer.

Published in:

Thoracic Cancer, 2025, v. 16, n. 1, p. 1, doi. 10.1111/1759-7714.70000

By:

Zou, Zihua;
Wu, Lige;
Hao, Xuezhi;
Li, Yan;
Liang, Li;
Gu, Yangchun;
Ying, Jianming;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.

Published in:

Thoracic Cancer, 2023, v. 14, n. 33, p. 3275, doi. 10.1111/1759-7714.15118

By:

Yaning Yang;
Guangjian Yang;
Weihua Li;
Xuezhi Hao;
Shuyang Zhang;
Xin Ai;
Siyu Lei;
Haiyan Xu;
Yan Wang

Publication type:

Article

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice.

Published in:

Thoracic Cancer, 2022, v. 13, n. 23, p. 3295, doi. 10.1111/1759-7714.14684

By:

Yang, Yaning;
Ai, Xin;
Xu, Haiyan;
Yang, Guangjian;
Yang, Lu;
Hao, Xuezhi;
Yang, Ke;
Mi, Yuling;
Wang, Guizhen;
Zhang, Shuyang;
Lei, Siyu;
Wang, Yan

Publication type:

Article

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences.

Published in:

Thoracic Cancer, 2022, v. 13, n. 22, p. 3105, doi. 10.1111/1759-7714.14659

By:

Xu, Fei;
Chen, Heng‐chi;
Xu, Haiyan;
Li, Junling;
Hao, Xuezhi;
Xing, Puyuan;
Ying, Jianming;
Wang, Yan

Publication type:

Article

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.

Published in:

Thoracic Cancer, 2022, v. 13, n. 1, p. 107, doi. 10.1111/1759-7714.14232

By:

Zou, Zihua;
Hao, Xuezhi;
Zhang, Cuiying;
Li, Haojing;
Dong, Guilan;
Peng, Yumei;
Ma, Kewei;
Guo, Ye;
Shan, Li;
Zhang, Yan;
Liang, Li;
Gu, Yangchun;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Published in:

Thoracic Cancer, 2021, v. 12, n. 21, p. 2924, doi. 10.1111/1759-7714.14156

By:

Li, Teng;
Wang, Shouzheng;
Ying, Jianming;
Wang, Yan;
Hu, Xingsheng;
Hao, Xuezhi;
Xu, Ziyi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.

Published in:

Thoracic Cancer, 2021, v. 12, n. 19, p. 2585, doi. 10.1111/1759-7714.14144

By:

Wang, Shouzheng;
Xie, Tongji;
Hao, Xuezhi;
Wang, Yan;
Hu, Xingsheng;
Wang, Lin;
Li, Yan;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC).

Published in:

Thoracic Cancer, 2021, v. 12, n. 17, p. 2360, doi. 10.1111/1759-7714.14078

By:

Xu, Ziyi;
Li, Teng;
Hu, Xingsheng;
Hao, Xuezhi;
Xing, Puyuan;
Li, Junling

Publication type:

Article

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

Published in:

Thoracic Cancer, 2021, v. 12, n. 16, p. 2233, doi. 10.1111/1759-7714.14057

By:

Xu, Ziyi;
Hao, Xuezhi;
Lin, Lin;
Li, Junling;
Xing, Puyuan

Publication type:

Article

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs.

Published in:

Thoracic Cancer, 2020, v. 11, n. 12, p. 3501, doi. 10.1111/1759-7714.13689

By:

Yang, Lu;
Hao, Xuezhi;
Hu, Xingsheng;
Wang, Zhijie;
Yang, Ke;
Mi, Yuling;
Yang, Yaning;
Xu, Haiyan;
Yang, Guangjian;
Wang, Yan

Publication type:

Article

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations.

Published in:

Thoracic Cancer, 2019, v. 10, n. 6, p. 1461, doi. 10.1111/1759-7714.13095

By:

Wang, Shouzheng;
Xing, Puyuan;
Yang, Ke;
Hao, Xuezhi;
Ma, Di;
Mu, Yuxin;
Li, Junling

Publication type:

Article

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib.

Published in:

Thoracic Cancer, 2019, v. 10, n. 5, p. 1213, doi. 10.1111/1759-7714.13071

By:

Ma, Di;
Zhang, Yan;
Xing, Puyuan;
Hao, Xuezhi;
Wang, Mengzhao;
Wang, Yan;
Shan, Li;
Xin, Tao;
Liang, Hongge;
Du, Yang;
Zhang, Zhaohui;
Liang, Li;
Li, Junling

Publication type:

Article

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance.

Published in:

Thoracic Cancer, 2019, v. 10, n. 5, p. 1096, doi. 10.1111/1759-7714.13050

By:

Xu, Haiyan;
Yang, Guangjian;
Yang, Lu;
Yang, Yaning;
Ma, Di;
Li, Junling;
Hao, Xuezhi;
Xing, Puyuan;
Wang, Yan

Publication type:

Article

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer.

Published in:

Thoracic Cancer, 2018, v. 9, n. 12, p. 1716, doi. 10.1111/1759-7714.12886

By:

Xing, Puyuan;
Mu, Yuxin;
Wang, Yan;
Hao, Xuezhi;
Zhu, Yixiang;
Hu, Xingsheng;
Wang, Hongyu;
Liu, Peng;
Lin, Lin;
Wang, Zhijie;
Li, Junling

Publication type:

Article

Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer.

Published in:

Thoracic Cancer, 2018, v. 9, n. 7, p. 805, doi. 10.1111/1759-7714.12650

By:

Xing, Puyuan;
Mu, Yuxin;
Wang, Yan;
Hao, Xuezhi;
Zhu, Yixiang;
Hu, Xingsheng;
Wang, Hongyu;
Liu, Peng;
Lin, Lin;
Wang, Zhijie;
Li, Junling

Publication type:

Article